Galapagos

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The heavy selling pressure might have exhausted for Galapagos (GLPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)

Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders' Meetings (AGM and EGM) to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm (CET) and 3:00 pm (CET), respectively, at the registered office of the Company.

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings

Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non-Independent Director by way of cooptation.

Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround

Galapagos has managed to curtail its R&D and G&A expenses, demonstrating efficient cost management. The company has strategically focused on oncology and immunology, sectors with high unmet medical needs and market impact potential. Galapagos is investing in CAR-T cell therapies, with promising early data indicating progress in its unique manufacturing platform.

Galapagos: Pipeline Still Progressing Despite Financial Volatility

Galapagos NV (GLPG) Q4 2023 Earnings Call Transcript

Full year 2023 key financials : Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023 Operational cash burn i of €414.8 million, within guidance 2023 and year-to-date key updates : Transferred Jyseleca® business, including approximately 400 positions, to Alfasigma S.p.A. Achieved encouraging data from ongoing Phase 1/2 studies with CD19 CAR-T product candidates, GLPG5101 in rrNHL and GLPG5201, in rrCLL, with or without RT Expanded CAR-T pipeline with start of Phase 1/2 study with BCMA CAR-T product candidate GLPG5301 in rrMM Enrolled first patients in Phase 2 study with TYK2 inhibitor, GLPG3667, in DM and SLE For strategic reasons, it was decided not to continue development of CD19 CAR-T candidate in rSLE Expanded point-of-care CAR-T network in the U.S. with manufacturing agreements with Landmark Bio and Thermo Fisher Scientific Signed strategic research and license collaboration with BridGene Biosciences in precision oncology Participated in Series C financing round of US-based precision oncology company, Frontier Medicines Appointed Thad Huston as CFO and COO, and Dr. Susanne Schaffert and Mr.

Galapagos announces full year 2023 results and outlook for 2024

Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies

Galapagos presents at EBMT-EHA annual meeting 2024

Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A.

Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

Thermo Fisher Scientific

Mechelen, Belgium; 4 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration agreement with Thermo Fisher Scientific, Inc. (NYSE: TMO) (“Thermo Fisher”) for the decentralized manufacturing of Galapagos' point-of-care CAR-T product candidate in the San Francisco area.

Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.

BridGene Eligible to Receive More Than $700 Million in Potential Upfront and Milestone Payments SAN JOSE, Calif. , Jan. 3, 2024 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditional "hard-to-drug" targets, announced today a strategic collaboration and licensing agreement with Galapagos NV (Euronext & NASDAQ: GLPG).

BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets

Mechelen, Belgium; 3 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. (“Bridgene”), a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates.

Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Mechelen, Belgium; 02 January 2024, 07:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and Alfasigma S.p.A. today announced that they have signed an agreement to transfer Galapagos' Jyseleca® (filgotinib) business to Alfasigma, marking a significant milestone in Galapagos' transformation into an innovative biotechnology company with a best-in-class research and development pipeline aimed at addressing high unmet patient needs in immunology and oncology. The agreement follows the signing of a letter of intent as announced on 30 October 2023.

Galapagos signs agreement to transfer Jyseleca® business to Alfasigma

Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the safety, efficacy, and feasibility of our seven-day vein-to-vein, point-of-care manufactured BCMA CAR-T candidate, GLPG5301, in adult patients with relapsed/refractory multiple myeloma (rrMM). This is Galapagos' third oncology CAR-T program in clinical development.

Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301

Banco Bilbao Vizcaya Argentaria

Tradeweb Markets

GLPG, BBVA and TW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 13, 2023.

Best Momentum Stocks to Buy for December 13th

Galapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET

Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101

Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST. The in-person event will be held at the San Diego Marriott Gaslamp Quarter in the Presidio Ballroom B/C. To register as an in-person attendee, please click here . To register as a virtual attendee, please click here .

Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023

Landmark Bio will serve as strategic point-of-care manufacturing partner for Galapagos' CAR-T product candidates in the Boston area WATERTOWN, Mass. , Nov. 6, 2023 /PRNewswire/ -- Landmark Bio, a collective endeavor bringing together leaders in industry, academia, and research hospitals to accelerate development and industrialization of next-generation genomic medicines, announced that it has signed a multi-year strategic manufacturing agreement with Galapagos NV (Euronext & NASDAQ: GLPG), an innovative biotech company with operations in Europe and the U.S. Under the terms of the agreement, Landmark Bio will perform GMP manufacturing of clinical trial batches of Galapagos' development programs of chimeric antigen receptor (CAR) T-cell therapies in hematology-oncology in the Boston metropolitan area.

Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care

Galapagos NV (NASDAQ:GLPG ) Q3 2023 Earnings Conference Call November 3, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO & COO Jeevan Shetty - Head of Clinical Development, Oncology Conference Call Participants Xian Deng - UBS Dane Leone - Raymond James Johoon Kim - RBC Capital Markets Jason Gerberry - Bank of America Sebastiaan van der Schoot - Kempen Jacob Mekhael - KBC Securities Operator Good day, and thank you for standing by. Welcome to the Galapagos Q3 2023 Financial Results Conference Call.

Galapagos NV (GLPG) Q3 2023 Earnings Call Transcript

Webcast presentation   tomorrow,   3   November 2023,   at 1 3 : 00 CET   /   8 :00 am ET,   www.glpg.com

Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023

Mechelen, Belgium; 30 October 2023, 21:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Alfasigma S.p.A. today announced that they have signed a letter of intent contemplating a transfer of the Jyseleca® business to Alfasigma, including the European and UK Marketing Authorizations, the commercial, medical and development activities for Jyseleca® and approximately 400 positions in 14 European countries.

Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma

Mechelen, Belgium; 1 9 September 2023, 22:01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 19 September 2023 , the Board of Directors appointed Mr. Simon Sturge as N o n- E xecutive I ndependent Director by way of cooptation . Mr. Sturge replaces Dr. Mary Kerr who stepped down on 18 September 2023 .

Galapagos appoints Simon Sturge to its Board of Directors

Mechelen, Belgium; 28 August 2023 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was randomized in GALACELA, a Phase 2 systemic lupus erythematosus (SLE) trial with GLPG3667.

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

Galapagos NV (NASDAQ:GLPG ) Q2 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO and COO Michele Manto - Chief Commercial Officer Daniele D'Ambrosio - Head of Immunology Conference Call Participants Emily Field - Barclays Jason Gerberry - Bank of America Mike Ulz - Morgan Stanley Brian Balchin - Jefferies Xian Deng - UBS Phil Nadeau - TD Cowen Dane Leone - Raymond James Sebastiaan van der Schoot - Kempen Jacob Mekhael - KBC Securities Operator Good day and thank you for standing by. Welcome to the Galapagos H1 2023 Financial Results Conference Call.

Galapagos NV (GLPG) Q2 2023 Earnings Call Transcript

Webcast presentation tomorrow, 4 August 2023, at 14:00 CET / 8:00 am ET, www.glpg.com

News for Galapagos Stock (GLPG)